Connor Clark & Lunn Investment Management Ltd. Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Connor Clark & Lunn Investment Management Ltd. increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 670.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,186 shares of the company’s stock after acquiring an additional 14,956 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Neurocrine Biosciences were worth $1,980,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. 1832 Asset Management L.P. increased its stake in shares of Neurocrine Biosciences by 1,370.7% in the second quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock worth $74,507,000 after purchasing an additional 504,400 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after buying an additional 363,863 shares in the last quarter. AQR Capital Management LLC increased its stake in Neurocrine Biosciences by 23.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after buying an additional 228,444 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after acquiring an additional 216,500 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Neurocrine Biosciences by 40.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock worth $97,828,000 after acquiring an additional 203,934 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 1.2 %

NBIX stock opened at $127.11 on Tuesday. Neurocrine Biosciences, Inc. has a 12 month low of $110.52 and a 12 month high of $157.98. The stock has a market cap of $12.87 billion, a PE ratio of 34.08 and a beta of 0.35. The company has a 50-day moving average price of $118.62 and a 200 day moving average price of $131.89.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Robert W. Baird lifted their target price on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Raymond James restated an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a report on Friday, November 1st. Finally, StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.